Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 151 Leukemia 67 Precursor Cell Lymphoblastic Leukemia-Lymphoma 29 Leukemia, Myelomonocytic, Acute 26 Leukemia, Monocytic, Acute 26 Myelodysplastic Syndromes 24 Leukemia, Erythroblastic, Acute 23 Leukemia, Megakaryoblastic, Acute 22 Congenital Abnormalities 21 Leukemia, Promyelocytic, Acute 13 Leukemia, Myelomonocytic, Chronic 12 Anemia, Refractory, with Excess of Blasts 12 Recurrence 8 Myeloproliferative Disorders 8 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8 Lymphoma 7 Leukemia, Myeloid, Chronic-Phase 7 Leukemia, Eosinophilic, Acute 7 Leukemia, Biphenotypic, Acute 7 Carcinoma, Hepatocellular 7 Leukemia, Basophilic, Acute 6 Blast Crisis 6 Neoplasm, Residual 4 Multiple Myeloma 4 Lymphoma, Non-Hodgkin 4 Lymphoma, Large B-Cell, Diffuse 4 Lymphoma, Follicular 4 Neutropenia 3 Neoplasms, Plasma Cell 3 Lymphoma, Large-Cell, Immunoblastic 3

Interventions

Cytarabine 6 Vincristine 4 Methotrexate 4 Mercaptopurine 4 pegaspargase 3 merphos 3 dexamethasone acetate 3 dexamethasone 21-phosphate 3 azathiopurine 3 auricularum 3 Thioguanine 3 Dexamethasone 3 Daunorubicin 3 Cyclophosphamide 3 Calcium Dobesilate 3 Asparaginase 3 prednylidene 2 blinatumomab 2 asparaginase erwinia chrysanthemi recombinant 2 Prednisolone 2 N,N-dicyclohexyl-isoborneol-10-sulfonamide 2 Leucovorin 2 Hydrocortisone 2 Etoposide 2 Doxorubicin 2 hydrocortisone hemisuccinate 1 deltacortene 1 calaspargase pegol 1 Spinal Puncture 1 Specimen Handling 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Down Syndrome × Idarubicin × Clear all

NCT07232134 2025-11-20

AML-DS-2025

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Phase 3 Recruiting

Other hematologic neoplasm

Down Syndrome, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡